LT3043773T - Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį - Google Patents

Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį

Info

Publication number
LT3043773T
LT3043773T LTEPPCT/IB2014/064251T LT14064251T LT3043773T LT 3043773 T LT3043773 T LT 3043773T LT 14064251 T LT14064251 T LT 14064251T LT 3043773 T LT3043773 T LT 3043773T
Authority
LT
Lithuania
Prior art keywords
olopatadine
mometasone
pharmaceutical composition
nasal administration
fixed dose
Prior art date
Application number
LTEPPCT/IB2014/064251T
Other languages
English (en)
Lithuanian (lt)
Inventor
Ulhas Dhuppad
Ashok KATKURWAR
Yashwant GUPTA
Rajesh ANKAM
Chandrakant DHATRAK
Original Assignee
Glenmark Specialty S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51688369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3043773(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Specialty S.A. filed Critical Glenmark Specialty S.A.
Publication of LT3043773T publication Critical patent/LT3043773T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
LTEPPCT/IB2014/064251T 2013-09-13 2014-09-04 Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį LT3043773T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2975MU2013 2013-09-13
PCT/IB2014/064251 WO2015036902A1 (en) 2013-09-13 2014-09-04 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Publications (1)

Publication Number Publication Date
LT3043773T true LT3043773T (lt) 2021-10-11

Family

ID=51688369

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2014/064251T LT3043773T (lt) 2013-09-13 2014-09-04 Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį

Country Status (23)

Country Link
US (1) US9078923B2 (enExample)
EP (2) EP3718533A1 (enExample)
JP (2) JP6203967B2 (enExample)
BR (1) BR112015018252B1 (enExample)
CY (1) CY1124675T1 (enExample)
DK (1) DK3043773T3 (enExample)
ES (1) ES2891729T3 (enExample)
FR (1) FR21C1057I2 (enExample)
HR (1) HRP20211515T1 (enExample)
HU (1) HUE056448T2 (enExample)
LT (1) LT3043773T (enExample)
MX (1) MX367674B (enExample)
MY (1) MY191380A (enExample)
NL (1) NL301154I2 (enExample)
NO (1) NO2021045I1 (enExample)
PH (1) PH12016500433B1 (enExample)
PL (1) PL3043773T3 (enExample)
PT (1) PT3043773T (enExample)
RS (1) RS62383B1 (enExample)
SI (1) SI3043773T1 (enExample)
SM (1) SMT202100563T1 (enExample)
UA (1) UA116793C2 (enExample)
WO (1) WO2015036902A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) * 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
UA116793C2 (uk) * 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
EP3279751A4 (en) 2015-04-03 2018-05-02 Lucis Technologies Holdings Limited Environmental control system
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
TWI790316B (zh) * 2017-12-14 2023-01-21 瑞士商葛蘭馬克專業股份公司 用於向人類經鼻投與之含有水性醫藥組合物的分配裝置
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2020070599A1 (en) * 2018-10-05 2020-04-09 Glenmark Specialty S.A. Nebulization composition of mometasone
CN109602693A (zh) * 2018-11-13 2019-04-12 华润三九(南昌)药业有限公司 糠酸莫米松凝胶及其制备方法
WO2021112242A1 (ja) * 2019-12-06 2021-06-10 東興薬品工業株式会社 ステロイド化合物およびオロパタジンを含有する医薬組成物
AU2021291684A1 (en) * 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
KR20260115848A (ko) 2023-11-21 2026-07-27 글렌마크 스페셜티 에스. 에이. 비강 분무 조성물
WO2025137749A1 (pt) * 2023-12-27 2025-07-03 Eurofarma Laboratórios S.A. Processo de solubilização de olopatadina e seu uso

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) * 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2504200A1 (en) * 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
PL1814538T3 (pl) * 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP1968548A2 (en) * 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
JP2009526063A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 医薬製剤
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2083798A1 (en) 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
CA2739353A1 (en) * 2008-10-10 2010-04-15 Schering Corporation Corticosteroid compositions and methods of treatments thereof
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) * 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
JP5683719B2 (ja) 2011-01-04 2015-03-11 イスタ・ファーマシューティカルズ・インコーポレイテッドIsta Pharmaceuticals,Inc. ベポタスチン組成物
FR2970180B1 (fr) 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
UA116793C2 (uk) * 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин

Also Published As

Publication number Publication date
JP2016534142A (ja) 2016-11-04
CY1124675T1 (el) 2022-07-22
NO2021045I1 (no) 2021-10-22
SMT202100563T1 (it) 2021-11-12
RU2015128497A (ru) 2017-10-18
WO2015036902A1 (en) 2015-03-19
FR21C1057I1 (fr) 2022-01-21
RU2015128497A3 (enExample) 2018-05-11
PT3043773T (pt) 2021-10-04
EP3043773A1 (en) 2016-07-20
PH12016500433B1 (en) 2023-03-01
JP2017206560A (ja) 2017-11-24
US20150079178A1 (en) 2015-03-19
JP6664358B2 (ja) 2020-03-13
MX2015013965A (es) 2016-02-10
EP3043773B1 (en) 2021-06-30
HUE056448T2 (hu) 2022-02-28
PH12016500433A1 (en) 2016-05-16
NL301154I2 (nl) 2022-07-18
FR21C1057I2 (fr) 2023-02-03
BR112015018252A2 (pt) 2017-07-18
PL3043773T3 (pl) 2021-12-13
MY191380A (en) 2022-06-21
MX367674B (es) 2019-08-30
EP3718533A1 (en) 2020-10-07
JP6203967B2 (ja) 2017-09-27
SI3043773T1 (sl) 2021-12-31
DK3043773T3 (da) 2021-10-04
HRP20211515T1 (hr) 2021-12-24
RS62383B1 (sr) 2021-10-29
UA116793C2 (uk) 2018-05-10
ES2891729T3 (es) 2022-01-31
BR112015018252B1 (pt) 2023-01-10
US9078923B2 (en) 2015-07-14
RU2687551C2 (ru) 2019-05-15

Similar Documents

Publication Publication Date Title
SMT202100563T1 (it) Composizione farmaceutica stabile a dose fissa comprendente mometasone e olopatadina per la somministrazione nasale
ZA201406233B (en) Pharmaceutical composition and administration thereof
IL240519B (en) History 1)]-n-heteroaryl-2-phenyl)ethyl]-(heterocyclyl-acetamide) and pharmaceutical preparations containing them
HUE051336T2 (hu) Többadagos gyógyszeradagoló eszköz
AP2015008875A0 (en) Low dose pharmaceutical composition
IL243786A0 (en) A drug that contains a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
ZA201507373B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
ZA201505318B (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
IL241917B (en) Formulations for subcutaneous administration of furosemide
ZA201507576B (en) Pharmaceutical combination drug
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
AP2015008208A0 (en) Pharmaceutical administration forms comprising
ZA201507706B (en) Inhalable pharmaceutical compositions and the inhaler devices containing them
PL3369429T3 (pl) Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa
GB201319437D0 (en) Delivery of drugs
SG11201602826VA (en) Icotinib-containing topical skin pharmaceutical compositions and uses thereof
LT2953617T (lt) Farmacinės kompozicijos, apimančios mažų dozių vaistus
GB201319924D0 (en) Improvements in drug delivery inhaler devices
PT3650024T (pt) Composição farmacêutica para administração nasal compreendendo rifampicinas para tratar demência
GB201216893D0 (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
ZA201503799B (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
PL2988782T3 (pl) Postacie dawkowania do podawania substancji czynnych drogą doustną
GB201308555D0 (en) Device for safe respiratory administration of volatile medicinal substances